TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis
Brief Summary: This study is for individuals with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophosphamide therapy by itself.


Options:
A: Arm Label: Cyclosporine A; Type: EXPERIMENTAL; Interventions: Drug: Cyclosporine A | Arm Label: Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Cyclosporine A; Assigned to Arm(s): Cyclosporine A | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: abatacept, Drug: cyclophosphamide, Drug: azathioprine, Drug: prednisone, Drug: azathioprine placebo | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: azathioprine, Drug: prednisone, Drug: abatacept placebo | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Control, Treatment | Intervention Type: DRUG; Name: azathioprine; Assigned to Arm(s): Control, Treatment | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Control, Treatment | Intervention Type: DRUG; Name: abatacept placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: azathioprine placebo; Assigned to Arm(s): Treatment
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus (FK506) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide or azathioprine | Intervention Type: DRUG; Name: tacrolimus (FK506); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: cyclophosphamide or azathioprine; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 811 | Arm Label: AMG811; Type: OTHER; Interventions: Drug: AMG 811 | Intervention Type: DRUG; Name: AMG 811; Assigned to Arm(s): AMG811, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome
Brief Summary: The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in subjects with carcinoid syndrome.


Options:
A: Arm Label: Octreotide+ Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Octreotide, Drug: Everolimus | Arm Label: Octreotide+ Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Octreotide, Drug: Placebo | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Octreotide+ Everolimus, Octreotide+ Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Octreotide+ Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Octreotide+ Everolimus
B: Arm Label: Lanreotide Autogel (Somatuline Depot) 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide | Arm Label: Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanreotide; Assigned to Arm(s): Lanreotide Autogel (Somatuline Depot) 120 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE
C: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Other: Best suportive care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best suportive care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: OTHER; Name: Best suportive care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
D: Arm Label: 177Lu-DOTA0-Tyr3-Octreotate; Type: EXPERIMENTAL; Interventions: Drug: Octreotide LAR, Drug: 177Lu-DOTA0-Tyr3-Octreotate | Arm Label: Octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide LAR | Intervention Type: DRUG; Name: Octreotide LAR; Assigned to Arm(s): 177Lu-DOTA0-Tyr3-Octreotate, Octreotide LAR | Intervention Type: DRUG; Name: 177Lu-DOTA0-Tyr3-Octreotate; Assigned to Arm(s): 177Lu-DOTA0-Tyr3-Octreotate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of a Positioning Pillow for Lumbar Puncture in Paediatric Hematology-Oncology
Brief Summary: We have developed a positioning cushion for LP which allows the child to be relaxed in an adequate position, and to maintain this position throughout LP. This study was aimed at evaluating the benefit of the device on the technical quality of LPs, on pain, anxiety, post LP syndrome, and on the satisfaction of children, their parents and caregivers.

The study was a two-centre, open, randomized trial, with two parallel groups. Children aged 2 to 18 years undergoing a LP were eligible, if not included in the study before. Those who had used the cushion before, with a medical reason preventing the use of the cushion, those refusing or whose parents refused could not be included. Randomization was stratified by centre.

Four cushion sizes were available for the age ranges: 2-6 years, 6-10 years, 10-15 and 15-18 years. The primary outcome was the rate of success, defined as a LP reaching its objective at the first attempt, without hemorrhage (visible hemorrhage or RBC \> 50/mm3 in the CSF sample). Secondary outcomes included: the child's pain using a visual analogic scale (VAS), parents and caregiver perception of the child's pain (VAS); the children, parents, caregiver and physician performing the LP satisfaction; children cooperation using the "Le Baron Scale", and the occurrence of a post LP syndrome.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: pillow | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pillow; Assigned to Arm(s): 1
B: Arm Label: OH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Arm Label: LH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Intervention Type: PROCEDURE; Name: Hernia repair; Assigned to Arm(s): LH, OH
C: Arm Label: Before Hidrotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hidrotherapy; Type: EXPERIMENTAL; Interventions: Other: Aquatic Physical Therapy | Intervention Type: OTHER; Name: Aquatic Physical Therapy; Assigned to Arm(s): Hidrotherapy
D: Arm Label: Pentacel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentacel (DPTaP+Hib) | Arm Label: Prevnar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prevnar (conjugated pneumococcal vaccine) | Intervention Type: DRUG; Name: Pentacel (DPTaP+Hib); Assigned to Arm(s): Pentacel | Intervention Type: DRUG; Name: Prevnar (conjugated pneumococcal vaccine); Assigned to Arm(s): Prevnar

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of a Positioning Pillow for Lumbar Puncture in Paediatric Hematology-Oncology
Brief Summary: We have developed a positioning cushion for LP which allows the child to be relaxed in an adequate position, and to maintain this position throughout LP. This study was aimed at evaluating the benefit of the device on the technical quality of LPs, on pain, anxiety, post LP syndrome, and on the satisfaction of children, their parents and caregivers.

The study was a two-centre, open, randomized trial, with two parallel groups. Children aged 2 to 18 years undergoing a LP were eligible, if not included in the study before. Those who had used the cushion before, with a medical reason preventing the use of the cushion, those refusing or whose parents refused could not be included. Randomization was stratified by centre.

Four cushion sizes were available for the age ranges: 2-6 years, 6-10 years, 10-15 and 15-18 years. The primary outcome was the rate of success, defined as a LP reaching its objective at the first attempt, without hemorrhage (visible hemorrhage or RBC \> 50/mm3 in the CSF sample). Secondary outcomes included: the child's pain using a visual analogic scale (VAS), parents and caregiver perception of the child's pain (VAS); the children, parents, caregiver and physician performing the LP satisfaction; children cooperation using the "Le Baron Scale", and the occurrence of a post LP syndrome.


Options:
A: Arm Label: Buzzy® device; Type: EXPERIMENTAL; Interventions: Device: Buzzy® device | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Buzzy® device; Assigned to Arm(s): Buzzy® device
B: Arm Label: Hypnovel® (midazolam); Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam oral intake | Arm Label: Electronic tab; Type: EXPERIMENTAL; Interventions: Procedure: electronic tab | Intervention Type: PROCEDURE; Name: electronic tab; Assigned to Arm(s): Electronic tab | Intervention Type: DRUG; Name: Midazolam oral intake; Assigned to Arm(s): Hypnovel® (midazolam)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: pillow | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pillow; Assigned to Arm(s): 1
D: Arm Label: Conventional syringe; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Camouflage syringe; Type: EXPERIMENTAL; Interventions: Procedure: Camouflage syringe | Intervention Type: PROCEDURE; Name: Camouflage syringe; Assigned to Arm(s): Camouflage syringe

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Placebo-controlled Study of Naltrexone in Trichotillomania
Brief Summary: This is an 8-week, double-blind study of Natrexone in the treatment of trichotillomania


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Dronabinol; Type: EXPERIMENTAL; Interventions: Drug: Dronabinol | Intervention Type: DRUG; Name: Dronabinol; Assigned to Arm(s): Dronabinol
C: Arm Label: N-acetylcysteine (NAC); Type: EXPERIMENTAL; Interventions: Drug: N-Acetylcysteine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N-acetylcysteine (NAC) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: N-Acetyl Cysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-Acetyl Cysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: N-Acetyl Cysteine; Assigned to Arm(s): N-Acetyl Cysteine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial Comparing Different Methods of Support With Stopping Smoking Offered Through The National Health Service (NHS) Smoking Helpline
Brief Summary: This study shall determine whether or not proactive telephone support for smoking cessation delivered to quitline callers is more effective than standard 'reactive' provision and whether or not the offer of a voucher for a cost free supply of nicotine replacement therapy (NRT) has any additional impact on smoking cessation rates achieved by behavioural interventions.


Options:
A: Intervention Type: DRUG; Name: rimonabant (SR141716); Assigned to Arm(s): N/A
B: Arm Label: PROOF cohort; Type: N/A; Interventions: Other: Sleep apnea/hypopnea detection | Intervention Type: OTHER; Name: Sleep apnea/hypopnea detection; Assigned to Arm(s): PROOF cohort
C: Arm Label: Standard support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support | Arm Label: Proactive telephone support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support | Arm Label: Standard support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Arm Label: Proactive support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Intervention Type: BEHAVIORAL; Name: Proactive telephone support; Assigned to Arm(s): Proactive support & offer NRT, Proactive telephone support | Intervention Type: BEHAVIORAL; Name: Reactive (standard) telephone support; Assigned to Arm(s): Standard support, Standard support & offer NRT | Intervention Type: DRUG; Name: Offer of voucher for cost-free Nicotine Replacement Therapy; Assigned to Arm(s): Proactive support & offer NRT, Standard support & offer NRT
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine versus placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: nicotine versus placebo | Intervention Type: DRUG; Name: nicotine versus placebo; Assigned to Arm(s): A, B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial Comparing Different Methods of Support With Stopping Smoking Offered Through The National Health Service (NHS) Smoking Helpline
Brief Summary: This study shall determine whether or not proactive telephone support for smoking cessation delivered to quitline callers is more effective than standard 'reactive' provision and whether or not the offer of a voucher for a cost free supply of nicotine replacement therapy (NRT) has any additional impact on smoking cessation rates achieved by behavioural interventions.


Options:
A: Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling delivered by telephone; Assigned to Arm(s): N/A
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: 2 mg nicotine polacrilex | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 2 mg nicotine polacrilex; Assigned to Arm(s): B
C: Arm Label: Standard support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support | Arm Label: Proactive telephone support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support | Arm Label: Standard support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Arm Label: Proactive support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Intervention Type: BEHAVIORAL; Name: Proactive telephone support; Assigned to Arm(s): Proactive support & offer NRT, Proactive telephone support | Intervention Type: BEHAVIORAL; Name: Reactive (standard) telephone support; Assigned to Arm(s): Standard support, Standard support & offer NRT | Intervention Type: DRUG; Name: Offer of voucher for cost-free Nicotine Replacement Therapy; Assigned to Arm(s): Proactive support & offer NRT, Standard support & offer NRT
D: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial Comparing Different Methods of Support With Stopping Smoking Offered Through The National Health Service (NHS) Smoking Helpline
Brief Summary: This study shall determine whether or not proactive telephone support for smoking cessation delivered to quitline callers is more effective than standard 'reactive' provision and whether or not the offer of a voucher for a cost free supply of nicotine replacement therapy (NRT) has any additional impact on smoking cessation rates achieved by behavioural interventions.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Tobacco Tactics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Tactics Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Tactics Intervention; Assigned to Arm(s): Tobacco Tactics Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Smoking cessation program; Type: EXPERIMENTAL; Interventions: Other: Smoking cessation program | Intervention Type: OTHER; Name: Smoking cessation program; Assigned to Arm(s): Smoking cessation program
C: Arm Label: Standard support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support | Arm Label: Proactive telephone support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support | Arm Label: Standard support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Arm Label: Proactive support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Intervention Type: BEHAVIORAL; Name: Proactive telephone support; Assigned to Arm(s): Proactive support & offer NRT, Proactive telephone support | Intervention Type: BEHAVIORAL; Name: Reactive (standard) telephone support; Assigned to Arm(s): Standard support, Standard support & offer NRT | Intervention Type: DRUG; Name: Offer of voucher for cost-free Nicotine Replacement Therapy; Assigned to Arm(s): Proactive support & offer NRT, Standard support & offer NRT
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Varenicline plus Motivational Interviewing counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Varenicline without counseling | Intervention Type: OTHER; Name: Varenicline plus Motivational Interviewing counseling; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Varenicline without counseling; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multi-center, Double-blind, Placebo-controlled, Cross-over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
Brief Summary: This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory classroom setting.


Options:
A: Arm Label: ADHD; Type: N/A; Interventions: N/A
B: Arm Label: Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) | Arm Label: Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR); Assigned to Arm(s): Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg, Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Methylphenidate Transdermal System (MTS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System (MTS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Lisdexamfetamine Dimesylate (LDX); Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine Dimesylate (LDX) | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine Dimesylate (LDX); Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B